KSQ Stock
HealthTechLooking to sell KSQ stock or options?
KSQ develops transformative medicines designed to accurately target the key nodes of disease. The company's industrialized functional genomics engine employs a range of tools to identify novel pathways and targets in oncology and immuno-oncology. This enables doctors to discover new drug targets, understand mechanisms of drug efficacy, and identify transformative single-agent and combination therapies to benefit patients.
Investors Include:
The Invus Group, Chimera Capital, Polaris Partners, ARCH Venture Partners, Cowen Healthcare Investments, Alpha Wave Global, Flagship Pioneering, Lilly Asia Ventures, Curie.Bio, Monroe Capital, Alexandria Real Estate Equities, Baillie Gifford.